| 脉痹丸治疗痰瘀阻络型颈动脉硬化伴易损斑块临床效果 |
| Clinical effect of Mai Bi pill in treating phlegm-stasis blocking collaterals type carotid atherosclerosis with vulnerable plaque |
| DOI： |
| 中文关键词: 颈动脉硬化 易损斑块 中医证候积分 脉痹丸 |
| 英文关键词: carotid atherosclerosis? vulnerable plaque? TCM syndrome score MaiBi pill |
| 基金项目:安徽省中医药传承创新科研项目(2022CCZD07)亳州市中医院工作室科研专项目(2021gzszx01) |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 目的 探讨脉痹丸治疗痰瘀阻络型颈动脉硬化伴易损斑块临床效果及其安全性。方法 选取亳州市中医院2023年01月—2023年12月治疗的颈动脉粥样硬化伴易损斑块患者 60 例,根据随机数字表法分为对照组30例与治疗组30例。对照组采取阿司匹林、瑞舒伐他汀钙片治疗,观察组在对照组基础上应用脉痹丸,比较两组患者治疗前后中医证候积分、颈动脉Crouse积分、同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)、脂蛋白相关磷脂酶A2(Lp-PLA2)、总胆固醇(CHOL)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C),并观察临床疗效及安全性。结果 总有效率观察组为 73.33% ,高于对照组的 40.00% ,组间相比,差异有统计学意义(P＜0.01)。治疗后,两组患者中医证候积分、颈动脉Crouse积分、同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)、脂蛋白相关磷脂酶A2(Lp-PLA2)、总胆固醇(CHOL)、低密度脂蛋白胆固醇(LDL-C)水平均低于治疗前；高密度脂蛋白胆固醇(HDL-C)高于治疗前,且治疗组均优于对照组,组内与组间比较,差异均有统计学意义(P＜0.05)。两组患者治疗期间未见严重不良反应,表现出良好的安全性。结论 颈动脉粥样硬化伴易损斑块痰瘀阻络型患者应用脉痹丸治疗的临床疗效确切,可显著降低中医证候积分,同时可减低颈动脉Crouse积分。同时有效降低Hcy、hs-CRP、Lp-PLA2、CHOL、LDL-C水平以及升高HDL-C水平。本研究提示脉痹丸安全性良好。 |
| 英文摘要: |
| Objective To explore the clinical effect and safety of MaiBi pill in the treatment of carotid arteriosclerosis with vulnerable plaque.Methods Selected 60 patients with carotid atherosclerosis with vulnerable plaque treated in Bozhou City Hospital of Traditional Chinese Medicine from January 2023 to December 2023, According to the random number table method, they were divided into the control group 30 cases and the treatment group 30 cases.The control group was treated with aspirin and rosuvastatin calcium tablets, and the observation group applied MaiBi pills on the basis of the control group, TCM syndrome scores, carotid Crouse scores,homocysteine (Hcy), hypersensitive C-reactive protein (hs-CRP) and lipoprotein associated phospholipase A2 (Lp-PLA2), total cholesterol (CHOL), low density lipoprotein cholesterin (LDL - C), high density lipoprotein cholesterol (HDL - C) were compared between the two groups before and after treatment. The clinical efficacy and safety were observed.Results The total effective rate of the observation group was 73.33%, which was higher than 40.00% of the control group. After statistical analysis, we found significant differences between the two groups. (P < 0.01).After treatment, the TCM syndrome score, carotid artery Crouse score, homocysteine (Hcy),? hypersensitive C-reactive protein (hs-CRP), lipoprotein associated phospholipase A2 (Lp-PLA2), total cholesterol (CHOL) and low-density lipoprotein cholesterol (LDL-C) levels of the two groups were lower than those before treatment;After treatment, the TCM syndrome score, carotid artery Crouse score, homocysteine (Hcy), hypersensitive C-reactive protein (hs-CRP),lipoprotein associated phospholipase A2 (Lp-PLA2), total cholesterol (CHOL) and low density lipoprotein cholesterol (LDL-C) levels of the two groups were lower than those before treatment. High density lipoprotein cholesterol (HDL-C) was higher than that before treatment, and each index in the treatment group was better than that in the control group, the difference was statistically significant (.P < 0.05).No serious adverse reactions were observed during treatment in the two groups, showing good safety.Conclusion The clinical effect of applying Maibi pill in the treatment of carotid atherosclerosis with vulnerable plaque phlegm-stasis blocking collaterals is exact.It can significantly reduce TCM syndrome score and carotid Crouse score.At the same time, it can effectively reduce the levels of Hcy, hs-CRP, Lp-PLA2, CHOL, LDL-C and increase the level of HDL-C.This study suggests that Maibi pill is safe. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|